Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer
Grant Data
Project Title
Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer
Principal Investigator
Dr Chan, Karen Kar Loen
(Co-Principal Investigator (Co-PI) (for projects led by other university))
Co-Investigator(s)
Professor Lui Vivian Wai Yan
(Project coordinator)
Duration
60
Start Date
2020-06-29
Amount
500000
Conference Title
Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer
Keywords
Precision Medicine Translation, Clinical Exceptional Responde, Gene-Drug Sensitivity Resource, Cancer
Discipline
CancerGenomic Medicine
HKU Project Code
R4015-19
Grant Type
Research Impact Fund (RIF) 2019/20
Funding Year
2019
Status
On-going
Objectives
(1) Per our clinical exceptional responder (ER) genetic database, we aim to generate all ERgenes/mutations in cancer cell models for high-content drug sensitivity analyses in vitro.(2) To establish animal models for all ER genes/mutations for the generation of in vivo drugsensitivity data on tumor growth, cell death and senescence.(3) To generate specific drug-response signature datasets for all ER genetic events by ""omics""technologies to infonnpotential patterns of remarkable drug-responses in cancer.(4) To create the first Hong Kong ER gene-drug evidence resource to guide precision medicineclinical trial design in oncology.